Chemomab Therapeutics Ltd DRC
$ 1.55
3.33%
24 Feb - close price
- Market Cap 9,232,700 USD
- Current Price $ 1.55
- High / Low $ 1.60 / 1.49
- Stock P/E N/A
- Book Value 1.82
- EPS -1.44
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.41 %
- ROE -0.73 %
- 52 Week High 7.04
- 52 Week Low 1.40
About
Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Tel Aviv, Israel.
Analyst Target Price
$17.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-14 | 2025-05-07 | 2025-03-05 | 2024-11-14 | 2024-08-21 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-14 | 2023-05-11 | 2023-03-20 |
| Reported EPS | -0.004 | -0.016 | -0.007 | -0.008 | -0.01 | -0.26 | -0.2753 | -0.2654 | -0.02 | -0.036 | -0.8 | -0.04 |
| Estimated EPS | -0.005 | -0.1 | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.04 |
| Surprise | 0.001 | 0.084 | 0.003 | 0.002 | 0 | -0.25 | -0.2453 | -0.2454 | 0 | -0.006 | -0.76 | 0 |
| Surprise Percentage | 20% | 84% | 30% | 20% | 0% | -2500% | -817.6667% | -1227% | 0% | -20% | -1900% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMMB
2026-02-17 13:27:40
Chemomab Therapeutics (Nasdaq: CMMB) announced that CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 8:00 am ET. The corporate presentation will be webcast live and available on the company's investor relations website for 90 days, with management also holding one-on-one investor meetings. Despite past negative market reactions to positive news, the company continues its investor outreach ahead of potential future nebokitug milestones.
2026-02-17 08:00:00
Chemomab Therapeutics Ltd. announced its participation in the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO Dr. Adi Mor and other senior management will provide a corporate presentation and engage in one-on-one investor meetings. The clinical-stage biotechnology company focuses on developing innovative therapeutics, such as nebokitug, for fibro-inflammatory diseases.
2026-02-17 05:00:00
Chemomab Therapeutics Ltd. will participate in the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO Dr. Adi Mor and other senior management members will deliver a corporate presentation and engage in one-on-one investor meetings at the event. The presentation will be webcast live and available on Chemomab's investor relations website for 90 days.
2026-02-11 06:28:16
Chemomab Therapeutics is moving its lead drug candidate, CM-101 (Nebokitug), towards a pivotal Phase 3 clinical trial for primary sclerosing cholangitis (PSC) after positive Phase 2 results. The company has secured regulatory feedback from the FDA and EMA for a single registration study and states it has sufficient liquidity through Q4 2026. Preparations for the Phase 3 trial are underway, and Chemomab is also exploring strategic partnerships and investigating CM-101 for systemic sclerosis, with upcoming catalysts including the trial launch and partnership updates.
2026-02-11 06:28:05
Chemomab Therapeutics is moving its lead drug candidate, CM-101 (Nebokitug), towards a pivotal Phase 3 clinical trial for primary sclerosing cholangitis (PSC) after positive mid-stage results and supportive feedback from the FDA and EMA. The company has sufficient liquidity until Q4 2026 and is seeking strategic partners while also exploring CM-101 for systemic sclerosis. The upcoming Phase 3 study initiation and partnership updates are key near-term catalysts for the company.
2026-02-06 22:30:05
This page provides news and market updates for Chemomab Therapeutics Ltd. (CMMB), a clinical-stage biotechnology company developing nebokitug for fibro-inflammatory diseases, particularly primary sclerosing cholangitis (PSC). It highlights the company's clinical trial results, regulatory milestones, financial updates, and investor outreach activities. Recent news focuses on positive Phase 2 SPRING trial data for nebokitug in PSC and progress towards Phase 3 trials and regulatory approval.
